Phase I study of the combination of disulfiram with cisplatin.
In light of preclinical evidence that disulfiram and related compounds decrease the toxicity and increase the therapeutic index of cisplatin, 12 patients were treated with a combination of cisplatin and oral disulfiram to determine the maximum tolerated dose of disulfiram that could be combined with cisplatin 100 mg/m2, and to determine the dose-limiting toxicity of disulfiram in this combination. Reversible confusion was the dose-limiting toxicity at a disulfiram dose of 3,000 mg/m2 administered 1 h before the end of a 2-h cisplatin infusion. A randomized study of cisplatin with or without disulfiram 2,000 mg/m2 p.o. is currently being conducted to determine the effect of disulfiram on cisplatin toxicity and pharmacology.
Ontario Cancer Treatment and Research Foundation, Ottawa Regional Cancer Centre, Canada.
D J
DJ
Stewart
S
S
Verma
J A
JA
Maroun
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D002945:Cisplatin / Q000008:administration & dosage; D004221:Disulfiram / Q000008:administration & dosage; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000188:drug therapy*
D002945:Cisplatin; D004221:Disulfiram